242 related articles for article (PubMed ID: 17353802)
1. Ezrin expression predicts survival in stage IIB osteosarcomas.
Kim MS; Song WS; Cho WH; Lee SY; Jeon DG
Clin Orthop Relat Res; 2007 Jun; 459():229-36. PubMed ID: 17353802
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.
Ferrari S; Zanella L; Alberghini M; Palmerini E; Staals E; Bacchini P
Pediatr Blood Cancer; 2008 Apr; 50(4):752-6. PubMed ID: 17886294
[TBL] [Abstract][Full Text] [Related]
3. Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma.
Park HR; Jung WW; Bacchini P; Bertoni F; Kim YW; Park YK
Pathol Res Pract; 2006; 202(7):509-15. PubMed ID: 16677779
[TBL] [Abstract][Full Text] [Related]
4. Immunoexpression of Ezrin and CD44 in patients with osteosarcoma.
Boldrini E; Peres SV; Morini S; de Camargo B
J Pediatr Hematol Oncol; 2010 Aug; 32(6):e213-7. PubMed ID: 20562647
[TBL] [Abstract][Full Text] [Related]
5. Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer.
Elzagheid A; Korkeila E; Bendardaf R; Buhmeida A; Heikkilä S; Vaheri A; Syrjänen K; Pyrhönen S; Carpén O
Hum Pathol; 2008 Dec; 39(12):1737-43. PubMed ID: 18701134
[TBL] [Abstract][Full Text] [Related]
6. Initial tumor size predicts histologic response and survival in localized osteosarcoma patients.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
J Surg Oncol; 2008 Apr; 97(5):456-61. PubMed ID: 18270971
[TBL] [Abstract][Full Text] [Related]
7. time dependency of prognostic factors in patients with stage II osteosarcomas.
Kim MS; Cho WH; Song WS; Lee SY; Jeon DG
Clin Orthop Relat Res; 2007 Oct; 463():157-65. PubMed ID: 17621233
[TBL] [Abstract][Full Text] [Related]
8. Differential presentations, clinical courses, and survivals of osteosarcomas of the proximal humerus over other extremity locations.
Cho WH; Song WS; Jeon DG; Kong CB; Kim MS; Lee JA; Yoo JY; Kim JD; Lee SY
Ann Surg Oncol; 2010 Mar; 17(3):702-8. PubMed ID: 19921336
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma.
Kilpatrick SE; Geisinger KR; King TS; Sciarrotta J; Ward WG; Gold SH; Bos GD
Mod Pathol; 2001 Dec; 14(12):1277-83. PubMed ID: 11743051
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
Ann Surg Oncol; 2008 Mar; 15(3):906-14. PubMed ID: 18163171
[TBL] [Abstract][Full Text] [Related]
11. Growth patterns of osteosarcoma predict patient survival.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Shin DS; Jeon DG
Arch Orthop Trauma Surg; 2009 Sep; 129(9):1189-96. PubMed ID: 18682966
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor expression in osteosarcoma.
Charity RM; Foukas AF; Deshmukh NS; Grimer RJ
Clin Orthop Relat Res; 2006 Jul; 448():193-8. PubMed ID: 16826116
[TBL] [Abstract][Full Text] [Related]
13. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma.
Sulzbacher I; Birner P; Trieb K; Träxler M; Lang S; Chott A
Mod Pathol; 2003 Jan; 16(1):66-71. PubMed ID: 12527715
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome.
Kersting C; Gebert C; Agelopoulos K; Schmidt H; van Diest PJ; Juergens H; Winkelmann W; Kevric M; Gosheger G; Brandt B; Bielack S; Buerger H
Clin Cancer Res; 2007 May; 13(10):2998-3005. PubMed ID: 17505002
[TBL] [Abstract][Full Text] [Related]
16. P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy.
Borys D; Canter RJ; Hoch B; Martinez SR; Tamurian RM; Murphy B; Bishop JW; Horvai A
Hum Pathol; 2012 Nov; 43(11):1948-54. PubMed ID: 22578565
[TBL] [Abstract][Full Text] [Related]
17. Primary versus radiation-associated craniofacial osteosarcoma: Biologic and clinicopathologic comparisons.
McHugh JB; Thomas DG; Herman JM; Ray ME; Baker LH; Adsay NV; Rabah R; Lucas DR
Cancer; 2006 Aug; 107(3):554-62. PubMed ID: 16795069
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma.
Kaseta MK; Khaldi L; Gomatos IP; Tzagarakis GP; Alevizos L; Leandros E; Papagelopoulos PJ; Soucacos PN
J Surg Oncol; 2008 Mar; 97(3):259-66. PubMed ID: 18161867
[TBL] [Abstract][Full Text] [Related]
19. A preliminary investigation of Beta-hCG expression in patients with osteosarcoma.
Masrouha KZ; Khattab R; Tawil A; Abdallah A; Saghieh S; Haidar R; Abboud M; Khoury NJ
J Bone Joint Surg Br; 2012 Mar; 94(3):419-24. PubMed ID: 22371553
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas.
Weng WH; Ahlén J; Aström K; Lui WO; Larsson C
Clin Cancer Res; 2005 Sep; 11(17):6198-204. PubMed ID: 16144921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
